Lynx DX, Inc
Lynx DX, Inc., based in Northville, MI, specializes in advanced diagnostic testing services, particularly in prostate cancer risk assessment. Their flagship product, MyProstateScore 2.0 (MPS2), offers a comprehensive urine test that evaluates 18 unique gene transcripts to predict the presence of clinically significant prostate cancer with enhanced accuracy.
With a focus on providing individualized reports, MPS2 allows physicians to tailor assessments based on unique patient contexts, offering flexibility in its application. The company is dedicated to improving patient outcomes and decision-making in urology by facilitating informed discussions around prostate cancer risks and management options.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.